Trials / Completed
CompletedNCT01710332
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Wills Eye · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.
Detailed description
Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravitreal Aflibercept Injection | GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total). GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total). |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2012-10-19
- Last updated
- 2017-06-16
- Results posted
- 2017-04-07
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01710332. Inclusion in this directory is not an endorsement.